Fused heterocyclic compounds as RET kinase inhibitors
US11964988B2 · kind B2 · utility
0Cited by
82References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 6, 2019 |
| Grant date | Apr 23, 2024 |
| Priority date | — |
| Expiry date | Jan 31, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.